ERBB2 and breast carcinoma: As for HER2 staining (p = 0.038), the rate of TFDP3 expression was 24.14% in the HER2-negative group (14 in 58 cases) and 50% in the HER2-positive group (19 in 38 cases) (Fig 4H), indicating that HER2 amplification might lead to TFDP3 activation in breast cancer.